Ultragenyx Pharma (RARE) Misses Q1 EPS by 8c

Ultragenyx Pharma (NASDAQ: RARE) reported Q1 EPS of ($1.82), $0.08 worse than the analyst estimate of ($1.74). Revenue for the quarter came in at $18.2 million versus the consensus estimate of $18.3 million.

For earnings history and earnings-related data on Ultragenyx Pharma (RARE) click here.

You May Also Be Interested In

• Ultragenyx Pharma (RARE) PT Lowered to $25 at H.C. Wainwright
• Intel (INTC) PT Lowered to $92 at Mizuho
• Torrid Holdings Inc. (CURV) Tops Q2 EPS by 8c; Offers Guidance